Compare Amphastar Pharmaceuticals Inc (AMPH) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Home Depot Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Home Depot Inc trades at $342.18 (market cap $342.31B). The key difference: Home Depot Inc is far larger — about 414.4× Amphastar Pharmaceuticals Inc's market cap, and Home Depot Inc pays a 2.71% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HD | |
|---|---|---|
Market Cap | $826.08M | $342.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $423.42 |
52-Week Low | $16.87 | $297.51 |
Enterprise Value | $1.22B | $403.87B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Home Depot (HD) trades at $343.30, up 1.35% with mixed technical signals showing bearish overall momentum but bullish moving averages. The company reported solid Q1 2026 earnings beat ($3.43 actual vs $3.41 expected) and maintains strong profitability with 33.13% gross margins. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $370.59 price target, representing 7.9% upside potential from current levels.
HD faces near-term headwinds from weakening big-ticket demand and margin pressure, but strong Pro business growth and housing market tailwinds support long-term prospects. The stock's current valuation at 24.38 P/E appears reasonable given consistent profitability and market leadership position. Key risks include rising mortgage rates impacting home improvement spending and competitive pressures in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
